{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:55:50Z","timestamp":1794099350242,"version":"4.8.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:sec id=\"ab-hbr230003-4\"><jats:title>Importance<\/jats:title><jats:p>Low-dose combination (LDC) antihypertensives consisting of 3 or 4 blood pressure (BP)\u2013lowering drugs have emerged as a potentially important therapy for the initial management of hypertension.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230003-5\"><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy and safety of LDC therapies for the management of hypertension.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230003-6\"><jats:title>Data Sources<\/jats:title><jats:p>PubMed and Medline were searched from date of inception until September 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230003-7\"><jats:title>Study Selection<\/jats:title><jats:p>Randomized clinical trials comparing LDC consisting of 3 or 4 BP-lowering drugs compared to either monotherapy, usual care, or placebo.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230003-8\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>Data were extracted by 2 independent authors and synthesized using both random and fixed-effects models using risk ratios (RR) for binary outcomes and mean differences for continuous outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230003-9\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was mean reduction in systolic BP (SBP) between LDC and monotherapy, usual care, or placebo. Other outcomes of interest included the proportion of patients achieving BP less than 140\/90 mm Hg, rates of adverse effects, and treatment withdrawal.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230003-10\"><jats:title>Results<\/jats:title><jats:p>Seven trials with a total of 1918 patients (mean [mean range] age, 59 [50-70] years; 739 [38%] female) were included. Four trials involved triple-component LDC and 3 involved quadruple-component LDC. At 4 to 12 weeks follow-up, LDC was associated with a greater mean reduction in SBP than initial monotherapy or usual care (mean reduction, 7.4 mm Hg; 95% CI, 4.3-10.5) and placebo (mean reduction, 18.0 mm Hg; 95% CI, 15.1-20.8). LDC was associated with a higher proportion of participants achieving BP less than 140\/90 mm Hg at 4 to 12 weeks compared to both monotherapy or usual care (66% vs 46%; RR, 1.40; 95% CI, 1.27-1.52) and placebo (54% vs 18%; RR, 3.03; 95% CI, 1.93-4.77). There was no significant heterogeneity between trials enrolling patients with and without baseline BP-lowering therapy. Results from 2 trials indicated LDC remained superior to monotherapy or usual care at 6 to 12 months. LDC was associated with more dizziness (14% vs 11%; RR 1.28, 95% CI 1.00-1.63) but no other adverse effects nor treatment withdrawal.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230003-11\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings in the study showed that LDCs with 3 or 4 antihypertensives were an effective and well-tolerated BP-lowering treatment option for the initial or early management of hypertension.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.0720","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:33:52Z","timestamp":1682523232000},"page":"606","source":"Crossref","is-referenced-by-count":63,"title":["Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension"],"prefix":"10.1001","volume":"8","author":[{"given":"Nelson","family":"Wang","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phidias","family":"Rueter","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Atkins","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Webster","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"School of Population Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Huffman","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Feinberg School of Medicine, Department of Preventive Medicine, Department of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Global Health Center, Cardiovascular Division, Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asita","family":"de Silva","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Chow","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Patel","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"hbr230003r1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"hbr230003r2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.5694\/mja2.2009.191.issue-6","article-title":"Gaps in cardiovascular disease risk management in Australian general practice.","volume":"191","author":"Webster","year":"2009","journal-title":"Med J Aust"},{"issue":"19","key":"hbr230003r3","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"hbr230003r4","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension.","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"7404","key":"hbr230003r5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"hbr230003r6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/HJH.0000000000002089","article-title":"Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials.","volume":"37","author":"Salam","year":"2019","journal-title":"J Hypertens"},{"issue":"1","key":"hbr230003r7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.117.09202","article-title":"Efficacy and safety of quarter-dose blood pressure\u2013lowering agents: a systematic review and meta-analysis of randomized controlled trials.","volume":"70","author":"Bennett","year":"2017","journal-title":"Hypertension"},{"key":"hbr230003r8","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.2147\/DDDT.S286586","article-title":"Low-dose triple antihypertensive combination therapy in patients with hypertension: a randomized, double-blind, phase II study.","volume":"14","author":"Hong","year":"2020","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"hbr230003r9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1161\/01.HYP.0000254479.66645.a3","article-title":"Low-dose quadruple antihypertensive combination: more efficacious than individual agents\u2013a preliminary report.","volume":"49","author":"Mahmud","year":"2007","journal-title":"Hypertension"},{"issue":"10073","key":"hbr230003r10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S0140-6736(17)30260-X","article-title":"Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.","volume":"389","author":"Chow","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"hbr230003r11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/jch.v24.10","article-title":"Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: a randomized, double-blind, parallel, phase II trial.","volume":"24","author":"Sung","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"7","key":"hbr230003r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041297","article-title":"Randomized polypill crossover trial in people aged 50 and over.","volume":"7","author":"Wald","year":"2012","journal-title":"PLoS One"},{"issue":"10305","key":"hbr230003r13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"hbr230003r14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial.","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"issue":"10022","key":"hbr230003r15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2804313\/jamacardiology_wang_2023_br_230003_1686672902.17302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T15:01:42Z","timestamp":1686754902000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2804313"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.0720","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}